PubMed Health⌕ Search

Biomedical subjects

T Inagami

Publications and source records attributed to T Inagami.

At least 163 records · Page 9Linked to original sources
PubMed1992

A newly found angiotensin II receptor subtype mediates cyclic GMP formation in differentiated Neuro-2A cells.

In search of the functional role of the newly found angiotensin II (Ang II) binding site which is expressed in differentiated Neuro-2A cells, we found that Ang II causes a marked stimulation of cGMP formation dose-dependently. The stimulation was blocked by the nonselective Ang II receptor antagonist [Sar1,Ile8]Ang II but not by the AT1 antagonist DuP 753 or the AT2 antagonist PD 123319. These results suggest that Ang II increased cGMP level via a new Ang II receptor subtype in differentiated Neuro-2A cells.

Angiotensin II↗
PubMed1992

Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor.

We isolated a cDNA encoding type-1 angiotensin II receptor from a human liver cDNA library. The cDNA had an open reading frame encoding a protein of 359 amino acid residues with a relative Mr of 41,060. The deduced amino acid sequence of the human angiotensin II (Ang II) receptor was 95.3% and 94.2% identical to those of bovine and rat type-1 Ang II receptors, respectively, and had a significant similarity with the G protein-coupled receptor. The rank order of the binding to the receptor expressed in COS-7 cells was Ang II greater than Ang III greater than Ang I. The expression of the Ang II receptor mRNA was detected in human liver, lung, adrenal and adrenocortical adenomas but not in adrenomedullary tumor, pheochromocytoma, by Northern blot analysis.

Amino Acid Sequence↗
PubMed1992

HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors.

HS-142-1, a novel microbial product, blocked 125I-labeled rat atrial natriuretic peptide (rANP) (= ANF(99-126)) binding to bovine adrenocortical membranes, where guanylyl cyclase-containing receptors are predominantly expressed. However, HS-142-1 only slightly inhibited [125I]rANP binding to bovine lung membranes where only a small portion of binding sites are coupled to guanylyl cyclase. Further, HS-142-1 only recognized the 135 kDa ANP receptor, which is considered to be the guanylyl cyclase-containing receptor based on the results obtained in affinity cross-linking studies with bovine adrenocortical and lung membranes. Under identical conditions, Atriopeptin I selectively recognized guanylyl cyclase-free receptors both in binding and affinity cross-linking experiments. When injected intravenously (1 mg/kg) to anesthetized rats, HS-142-1 abolished ANP-induced diuresis and natriuresis. These results suggest that HS-142-1 works in vivo through a specific interaction with the ANP functional receptor, and that HS-142-1 will be a powerful tool for understanding the physiological roles of ANP in distinction from its pharmacological effects.

Adrenal Glands↗
PubMed1992

Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor.

The gene of human angiotensin II type 1 (AT1) receptor was isolated from a lymphocyte genomic library. The coding region of the human AT1 receptor gene was contained in a single exon coding segment of the gene indicating an intronless structure of the coding region. The amino acid sequence of human AT1 receptor deduced from its base sequence has 359 amino acids and showed a high degree of sequence identity to bovine and rat AT1 receptor sequences. Amino acid substitutions specific to the human AT1 receptor were mostly confined to the carboxy terminal half of the molecule. The seven-transmembrane domains are well-conserved in those sequences.

Amino Acid Sequence↗
PubMed1992

Identification of two subtypes in the rat type I angiotensin II receptor.

A rat adrenal cDNA library was screened by colony hybridization using a rat cDNA fragment of type I angiotensin II receptor (AT1A) previously isolated from the kidney. Two cDNA clones were identified, designated as AT1B, to have a nucleotide sequence highly homologous to and yet distinct from AT1A. The amino acid sequence of AT1B consists of 359 amino acid residues and has 96% identity with AT1A. No conspicuous difference in the ligand binding characteristics was observed between AT1A and AT1B. The mRNA for AT1B was expressed in many tissues as is the case with AT1A, and most abundantly expressed in the adrenal glands in the Sprague-Dawley rats. The existence of two subtypes in the rat type I angiotensin II receptor might explain the diverse actions of angiotensin II in various tissues.

Amino Acid Sequence↗
PubMed1992

Regulation of the expression of the rat angiotensin II receptor mRNA.

Regulation of the expression levels of the rat angiotensin II receptor mRNA in the adrenal, aorta, kidney, and brain was assessed by the competitive polymerase chain reaction method. The bilateral nephrectomy or the administration of Dup753 markedly reduced the expression levels of this receptor mRNA in the adrenal and brain stem, but not in the kidney nor aorta. A continuous infusion of angiotensin II increased the expression level of this receptor mRNA in the adrenal but not in the other tissues. It is suggested that the expression level of this receptor mRNA in the adrenal is dependent on the renin angiotensin aldosterone system.

Actins↗
PubMed1992

Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells.

Specific binding site for 125I-angiotensin II (Ang II), with unique pharmacological properties uncommon to the hitherto recognized receptor subtypes, was observed in mouse neuroblastoma cells (Neuro-2A). Differentiation of the cells with 100 nM PGE1 resulted in a 10-fold increase in the number of Ang II binding sites without changing the binding affinity (Kd value: 12.0 nM). 125I-Ang II binding to membranes of differentiated Neuro-2A was inhibited by unlabeled Ang II with a Ki value of 7.06 +/- 1.09 nM but not by Ang III (1 microM). Both AT1 antagonist, Dup753, and AT2 antagonist, PD123319, failed to inhibit 125I-Ang II binding at 1 microM. 125I-Ang II binding was not affected by GTP analogs such as GTP gamma S and Gpp(NH)p. These results suggest that Neuro-2A cells possess a binding site for Ang II which is different from the presently known subtypes of Ang II receptors, and that the number of the binding site is regulated by cell differentiation.

Angiotensin II↗
PubMed1992

Endothelin-1 receptor antagonist: effects on endothelin- and cyclosporine-treated mesangial cells.

Endothelin-1 (Et) has profound effects on glomerular microcirculation and mesangial cell contraction. A parameter of mesangial cell contraction was examined by measuring myosin light chain phosphorylation (MLCP) in glomerular mesangial cells in the presence and absence of a newly developed endothelin-1 receptor antagonist (EtA). Addition of Et alone (10 nM) caused a marked increase in MLCP, which, on average, rose by 53 +/- 6% above the level in cells exposed to vehicle (P less than 0.0005). This effect was shown to continue for at least one hour; MLCP at 60 minutes was 64 +/- 12% higher than controls, (P less than 0.025), constituting a unique observation of an in vitro parameter which parallels the characteristic in vivo effect of Et. Treatment of cells with EtA virtually abolished this Et-induced increase in MLCP, which rose by only 2 +/- 3% and -1 +/- 4% for doses of EtA of 44 nM and 66 nM, respectively. Examination of the intracellular calcium concentration, [Ca2+]i, revealed that EtA almost completely abolished the transient increase in [Ca2+]i evoked by Et and also suppressed the early portions of the sustained increase in [Ca2+]i. EtA was ineffective in abolishing [Ca2+]i increase in response to arginine vasopressin. Finally, to evaluate EtA's efficacy in a pathophysiologic setting, we also studied mesangial cells exposed to cyclosporine (Cs). Exposure of mesangial cells to Cs (10(-5) M) for 60 minutes caused a significant increase in MLCP, on average, by 38 +/- 6% above control (P less than 0.0005), while cells exposed to Cs in the presence of EtA increased MLCP significantly less, by only 15 +/- 9%. These data provide further evidence for Et's long-lasting cellular actions, and demonstrate inhibitory effects of an Et receptor antagonist after direct cellular exposure to Et and also after Cs exposure, a pathophysiologic setting which likely involves Et.

Amino Acid Sequence↗
PubMed1992

Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease.

Evidence suggests an important role for the renin-angiotensin system in the pathogenesis of autosomal-dominant polycystic kidney disease (ADPKD). Therefore, we studied the presence of immunoreactive renin in renal biopsies and measured the concentrations of renin in cyst fluids. Normal kidneys and kidneys with renal artery stenosis were used for comparison. In ADPKD, immunoreactive renin was present in juxtaglomerular apparatus, associated arterioles, and in some cells within the connective tissue surrounding the cysts. Vascular immunoreactive renin was less prominent than in renal artery stenosis. Increased amounts of tubular immunoreactive renin were noted in polycystic kidneys, as compared to normal kidneys and kidneys with renal artery stenosis. Cyst fluids contained renin detected by Western analysis and enzymatic activity; concentrations were greater in gradient cysts than in nongradient cysts. Seventy-four percent of the renin in gradient cysts was active as compared to 23% in nongradient cysts and 15% in plasma. To determine whether cyst epithelial cells are capable of synthesizing renin, these cells were isolated in tissue culture. Enzymatic assay of extracts from these cells revealed the presence of renin-like enzymatic activity (1.3 +/- 0.8 ng AI/mg protein/hr). The synthesis of renin by tubulocystic epithelium was confirmed by [35S]-methionine radiolabeling of cyst-derived cells, followed by immunoprecipitation and SDS-PAGE and by detection of renin mRNA by the polymerase chain reaction. These results indicate that the tubulocystic epithelium has the potential to synthesize renin. Elevated levels of active renin in renal cysts may be linked to the pathogenesis of hypertension in ADPKD. The occurrence of renin in the lining epithelium of cyst walls raises the possibility that abnormal expression of the renin-angiotensin system may, by a paracrine or autocrine mechanism, regulate epithelial hyperplasia in growing renal cysts.

Base Sequence↗
PubMed1992

Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity.

Endothelin (Et) has been implicated in cyclosporine A (CsA) nephrotoxicity. We have previously shown that CsA treatment in rats results in up-regulation of Et receptors specifically within the kidney. The role of Et in vivo CsA nephrotoxicity was therefore studied further with a new competitive antagonist, BQ-123, specific for Et(A) receptors (EtRA). Systemic administration of CsA in Munich-Wistar rats resulted in marked glomerular hypoperfusion and hypofiltration, with RPF in left and right kidneys falling by some 40% to 1.60 +/- 0.25 and 1.73 +/- 0.38 ml/min and GFR decreasing by some 20% to 0.61 +/- 0.05 and 0.67 +/- 0.11 ml/min, respectively. Selective infusion of EtRA into the left renal artery following systemic CsA treatment had no effect on this hemodynamic pattern (RPF 1.58 +/- 0.29 and 1.92 +/- 0.34 ml/min and GFR 0.60 +/- 0.09 and 0.70 +/- 0.08 ml/min in left and right kidneys, respectively, P = NS vs. CsA period). By contrast, intrarenal infusion of EtRA prior to systemic administration of CsA resulted in a strikingly different pattern of renal hemodynamics. Thus, EtRA pretreatment in the left kidney protected against glomerular dysfunction following CsA: RPF was maintained, 3.23 +/- 0.28 ml/min versus 2.96 +/- 0.31 (P = NS EtRA vs. EtRA + CsA), as was the GFR, 1.04 +/- 0.16 ml/min versus 1.12 +/- 0.09 (P = NS). However, the contralateral right kidneys of these rats, not pretreated with EtRA, showed no protective effect: RPF decreased from 3.15 +/- 0.34 ml/min to 2.39 +/- 0.19 and GFR from 1.04 +/- 0.10 ml/min to 0.85 +/- 0.07 (P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Acute Disease↗
PubMed1992

Identification of a candidate gene responsible for the high blood pressure of spontaneously hypertensive rats.

OBJECTIVE: We have recently isolated a gene, designated as the SA gene, which is more than 10 times more abundantly expressed in the kidneys of spontaneously hypertensive rats (SHR) than in those of Wistar-Kyoto (WKY) rats. To address the issue whether the SA gene is one of the genes responsible for the hypertension of SHR, a genetic cosegregation analysis of the blood pressure values with the genotypes in an F2 rat population was undertaken in this study. METHODS AND DESIGN: Male F2 rats were bred from SHR and WKY rats. The genotypes of the SA gene of the F2 rats were determined by utilizing the StuI restriction fragment length polymorphism of the SA gene between SHR and WKY rats. The blood pressure values were determined by the tail-cuff method. The effect of the genotype of the SA gene on the blood pressure of the F2 rats was analysed by one-way analysis of variance. RESULTS AND CONCLUSION: The blood pressure of the F2 rats inheriting two SHR alleles of the SA gene was significantly higher than that of the F2 rats inheriting two WKY alleles. This indicates that the SA gene, or a gene closely linked to it, has a capacity to influence the blood pressure values of the F2 rat population. Further studies to identify functions of the SA gene products will be necessary.

Animals↗
PubMed1992

Renin and angiotensinogen expression during the evolution of diabetes.

The expression of renin and angiotensinogen genes and their proteins were studied during the progression of diabetes using adult BioBreeding spontaneously diabetic rats at 1 day and 2-12 months of diabetes. The number of renin-stained cells per juxtaglomerular apparatus was determined by immunocytochemistry. Initially, at 2 months of diabetes the number of renin-stained cells per juxtaglomerular apparatus increased significantly (p less than 0.0001, 2 months versus resistant groups) and was followed by a decrease in the number and intensity of renin-stained cells after 12 months of diabetes (p = 0.007, 2 months versus 12 months). A significant negative correlation was observed between the number of renin-containing cells and the duration of diabetes (r = 0.99, p = 0.014). Immunoreactive angiotensinogen was restricted to the proximal tubule and appeared increased after 4 and 8 months of diabetes as compared with the 2- and 12-month diabetic groups. Renin messenger RNA (mRNA) levels increased with the onset of diabetes and decreased markedly during chronic diabetes. At 1 day of diabetes, renin mRNA levels were 700% higher than at 12 months of diabetes. Angiotensinogen mRNA levels were unchanged. We conclude that diabetes results in an initial increase in renin gene expression, and as the duration of diabetes lengthens, there is a progressive decrease in renin gene expression and in the number of cells containing renin. These findings suggest that as the duration of diabetes and the age of the animal lengthens, there is a decrease in the number of cells expressing the renin gene.

Angiotensinogen↗
PubMed1992

Localization of components of the renin-angiotensin system within the kidney and sustained release of angiotensins from isolated and perfused kidney.

We found colocalization of renin, angiotensin (Ang) I and Ang II in juxtaglomerular (JG) cells of the kidney. Coexistence of Ang II in renin granules was demonstrated by electron microscopic immunogold labeling of these components. Coexistence of both Ang I and Ang II in the high density renin storage granules were also demonstrated by gradient centrifugation of renal homogenate. These findings supported the synthesis of Ang I and Ang II in juxtaglomerular cells. Isolated and cultured JG cells showed the synthesis of Ang I, Ang II and renin. Ang I and Ang II were secreted from isolated and perfused rat kidneys at steady rates over 2 hr. Their secretion rates were proportional to that of renin. The rate of Ang II secretion from the kidney was higher than that from the vascular bed. Ang II was also found in renal lymph. These findings indicate that a large amount of Ang II is generated in JG cells by the intracellular action of renin and may play a significant role in the regulation of renal function.

Angiotensins↗
PubMed1992

Quantitative analysis of renin gene expression in extrarenal tissues by polymerase chain reaction method.

OBJECTIVE: To evaluate the significance of locally synthesized renin in the pathogenesis of hypertension, we investigated modulation of the renin gene expression in extrarenal tissues. DESIGN: Expression levels of renin messenger (m)RNA in various tissues were determined in the genetically hypertensive rats and their control strains. Effects of salt, captopril and clonidine upon renin gene expression were also investigated. METHODS: Due to the very low expression level of renin mRNA in extrarenal tissues, a competitive polymerase chain reaction method of assessment was applied. Total RNA from various tissues combined with a synthetic deletion-mutated renin RNA were reverse-transcribed and the resultant complementary DNA mixtures were amplified in one reaction in which the same primers were used. RESULTS: Expression levels of the renin mRNA in various parts of the central nervous system of 4-week-old spontaneously hypertensive rats were approximately twofold higher than those of age-matched Wistar-Kyoto rats and expression levels in the brain were positively modulated by the administration of either captopril or clonidine. CONCLUSIONS: The importance of the brain renin angiotensin system in the pathogenesis of hypertension in spontaneously hypertensive rats was strongly suggested.

Adrenal Glands↗
PubMed1991

Phospholipase D in cultured rat vascular smooth muscle cells and its activation by phorbol ester.

We determined the phospholipase D (PLD) activity in rat vascular smooth muscle cells by the formation of phosphatidylethanol in cells prelabeled with [3H] myristic acid. The enzyme was markedly activated by a phorbol ester (TPA). Down regulation of protein kinase C (PKC) resulted in almost complete inhibition indicating PKC-dependent mechanism of its activation. Depletion of calcium by EGTA and TMB-8 caused 53% inhibition. Chelator-stable association of PKC to membrane by TPA was observed in the absence of extracellular Ca2+. The mitogenic peptide PDGF also caused a marked stimulation of PLD. These results indicate that PLD in vascular smooth muscle cells is stimulated by TPA through the activation of PKC both by calcium-dependent and independent mechanisms.

Animals↗
PubMed1991

Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression.

The nucleotide and amino acid sequences for rat type I angiotensin II receptor were deduced through molecular cloning and sequence analysis of its complementary DNAs. The rat angiotensin II receptor consists of 359 amino acid residues and has a sequence similar to G protein-coupled receptors. The expression of this receptor gene was detected in the adrenal, liver and kidney by Northern blotting. Sodium deprivation positively modulated the expression of the receptor gene in the adrenal. No detectable change was observed in the expression levels of this receptor gene between spontaneously hypertensive rats and Wistar-Kyoto rats in the tissues examined including the adrenal, brain, kidney and liver. Interestingly the expression of this receptor gene was developmentally regulated.

Amino Acid Sequence↗
PubMed1991

Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor.

Angiotensin II elicits different responses which affect cardiovascular, neuronal and electrolyte transport regulation. To understand the mechanisms responsible for its various actions, the receptor for angiotensin II has long been sought, but numerous attempts to purify the receptor have been unsuccessful owing to its instability and low concentration. We report here the expression cloning of a complementary DNA encoding a bovine angiotensin II receptor to overcome these difficulties. The receptor cDNA encodes a protein of 359 amino-acid residues with a transmembrane topology similar to that of other G protein-coupled receptors. COS-7 cells transfected with the cDNA expressed specific and high-affinity binding sites for angiotensin II, angiotensin II antagonist and a non-peptide specific antagonist for type-1 receptor. Dithiothreitol inhibited ligand binding. The concentration of intracellular Ca2+ and of inositol-1,4,5-trisphosphate increased in the transfected COS-7 cells in response to angiotensin II or angiotensin III, indicating that this receptor is the type-1 receptor for angiotensin II. Northern blot analysis revealed that the messenger RNA for this receptor is expressed in bovine adrenal medulla, cortex and kidney.

Adrenal Cortex↗